- Home
- VRAX vs CNSP Comparison
VRAX vs CNSP Comparison
Compare VRAX & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | CNSP |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 4.3M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | VRAX | CNSP |
|---|---|---|
| Price | $0.41 | $7.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 15.3M | 10.3K |
| Earning Date | 01-01-0001 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,986.00 | N/A |
| Revenue This Year | $217,274.83 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.35 | $4.93 |
| 52 Week High | $3.20 | $114.00 |
Technical Indicators
Market Signals| Indicator | VRAX | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 46.79 |
| Support Level | $0.39 | $7.01 |
| Resistance Level | $0.50 | $8.10 |
| Average True Range (ATR) | 0.07 | 0.56 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 3.69 | 39.70 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.